A carregar...
IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
Background: The efficacy of an EGFR-targeted treatment strategy for non-small cell lung cancer (NSCLC) is reduced by drug resistance. IL-22 enhances tumor growth and induces chemotherapy resistance in human lung cancer cells. The present study elucidated the IL-22-induced mechanism underlying EGFR-t...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6848259/ https://ncbi.nlm.nih.gov/pubmed/31750252 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01167 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|